Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Huayu Bushen is a compound traditional Chinese herbal medicine (TCM) formulated as a granule. It is primarily investigated for the treatment of cervical spondylotic myelopathy and cervical syndrome, specifically addressing the TCM syndromes of Qi deficiency, blood stasis, and kidney deficiency. The recipe's mechanism involves delaying intervertebral disc degeneration by regulating the metabolism of the extracellular matrix (ECM). It promotes the expression of aggrecan and type II collagen while inhibiting the expression of type X collagen and matrix metalloproteinase-13 (MMP-13). Additionally, it upregulates tissue inhibitor of metalloproteinase-1 (TIMP-1), thereby restoring the balance between ECM synthesis and degradation. Research also suggests it may influence the immune, endocrine, and coagulation systems, including the regulation of serum estradiol levels and hemorheological parameters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqi huayu bushen.